203 related articles for article (PubMed ID: 19383782)
21. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance.
Kobayashi H; Dubois S; Sato N; Sabzevari H; Sakai Y; Waldmann TA; Tagaya Y
Blood; 2005 Jan; 105(2):721-7. PubMed ID: 15367431
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cell-induced activation of adaptive and innate antitumor immunity.
van den Broeke LT; Daschbach E; Thomas EK; Andringa G; Berzofsky JA
J Immunol; 2003 Dec; 171(11):5842-52. PubMed ID: 14634094
[TBL] [Abstract][Full Text] [Related]
23. Cell-Based IL-15:IL-15Rα Secreting Vaccine as an Effective Therapy for CT26 Colon Cancer in Mice.
Thi VAD; Jeon HM; Park SM; Lee H; Kim YS
Mol Cells; 2019 Dec; 42(12):869-883. PubMed ID: 31760731
[TBL] [Abstract][Full Text] [Related]
24. Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.
Johnson EE; Buhtoiarov IN; Baldeshwiler MJ; Felder MA; Van Rooijen N; Sondel PM; Rakhmilevich AL
J Immunother; 2011 Jan; 34(1):76-84. PubMed ID: 21150715
[TBL] [Abstract][Full Text] [Related]
25. Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study.
Johnson P; Challis R; Chowdhury F; Gao Y; Harvey M; Geldart T; Kerr P; Chan C; Smith A; Steven N; Edwards C; Ashton-Key M; Hodges E; Tutt A; Ottensmeier C; Glennie M; Williams A
Clin Cancer Res; 2015 Mar; 21(6):1321-8. PubMed ID: 25589626
[TBL] [Abstract][Full Text] [Related]
26. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
[TBL] [Abstract][Full Text] [Related]
27. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
28. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.
Kosaka A; Ohkuri T; Okada H
Cancer Immunol Immunother; 2014 Aug; 63(8):847-57. PubMed ID: 24878890
[TBL] [Abstract][Full Text] [Related]
29. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans.
Rowley J; Monie A; Hung CF; Wu TC
J Immunol; 2008 Dec; 181(12):8237-47. PubMed ID: 19050240
[TBL] [Abstract][Full Text] [Related]
31. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.
Murphy WJ; Welniak L; Back T; Hixon J; Subleski J; Seki N; Wigginton JM; Wilson SE; Blazar BR; Malyguine AM; Sayers TJ; Wiltrout RH
J Immunol; 2003 Mar; 170(5):2727-33. PubMed ID: 12594303
[TBL] [Abstract][Full Text] [Related]
32. Recombinant human prolactin improves antitumor effects of murine natural killer cells in vitro and in vivo.
Sun R; Wei H; Zhang J; Li A; Zhang W; Tian Z
Neuroimmunomodulation; 2002-2003; 10(3):169-76. PubMed ID: 12481157
[TBL] [Abstract][Full Text] [Related]
33. Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model.
Wu Y; Deng Z; Wang H; Ma W; Zhou C; Zhang S
BMC Immunol; 2016 Sep; 17(1):29. PubMed ID: 27645787
[TBL] [Abstract][Full Text] [Related]
34. Continuous release of interleukin 12 from microencapsulated engineered cells for colon cancer therapy.
Zheng S; Xiao ZX; Pan YL; Han MY; Dong Q
World J Gastroenterol; 2003 May; 9(5):951-5. PubMed ID: 12717836
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of myeloid dendritic cells retrovirally transduced to express mammalian or viral interleukin-10 on cytotoxic T lymphocyte and natural killer cell functions and resistance to tumor growth.
Takayama T; Tahara H; Thomson AW
Transplantation; 2001 May; 71(9):1334-40. PubMed ID: 11397973
[TBL] [Abstract][Full Text] [Related]
36. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.
Buhtoiarov IN; Lum H; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Immunol; 2005 May; 174(10):6013-22. PubMed ID: 15879094
[TBL] [Abstract][Full Text] [Related]
37. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation.
Pan PY; Gu P; Li Q; Xu D; Weber K; Chen SH
J Immunol; 2004 Apr; 172(8):4779-89. PubMed ID: 15067054
[TBL] [Abstract][Full Text] [Related]
38. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
Anderson PM; Blazar BR; Bach FH; Ochoa AC
J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
[TBL] [Abstract][Full Text] [Related]
39. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
40. Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases.
von Scheidt B; Leung PS; Yong MC; Zhang Y; Towne JE; Smyth MJ; Teng MW
Cancer Res; 2014 May; 74(9):2412-21. PubMed ID: 24556719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
